Figure 1From: Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer The incidence of adverse events in patients. The incidence of AEs was assessed on treatment days 7, 14, 21, and 28. The grades of AEs were assessed using the grading system of Common Terminology Criteria for Adverse Events (version 4.0).Back to article page